These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 31396933)

  • 1. In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC.
    Ueda T; Kaneko S
    Methods Mol Biol; 2019; 2048():85-91. PubMed ID: 31396933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiating CD8αβ T Cells from TCR-Transduced iPSCs for Cancer Immunotherapy.
    Minagawa A; Kaneko S
    Methods Mol Biol; 2019; 2048():81-84. PubMed ID: 31396932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in CAR-T cell engineering.
    Huang R; Li X; He Y; Zhu W; Gao L; Liu Y; Gao L; Wen Q; Zhong JF; Zhang C; Zhang X
    J Hematol Oncol; 2020 Jul; 13(1):86. PubMed ID: 32616000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized Production of Lentiviral Vectors for CAR-T Cell.
    Moço PD; de Abreu Neto MS; Fantacini DMC; Picanço-Castro V
    Methods Mol Biol; 2020; 2086():69-76. PubMed ID: 31707668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
    Rozenbaum M; Meir A; Aharony Y; Itzhaki O; Schachter J; Bank I; Jacoby E; Besser MJ
    Front Immunol; 2020; 11():1347. PubMed ID: 32714329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.
    Monjezi R; Miskey C; Gogishvili T; Schleef M; Schmeer M; Einsele H; Ivics Z; Hudecek M
    Leukemia; 2017 Jan; 31(1):186-194. PubMed ID: 27491640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives.
    Labbé RP; Vessillier S; Rafiq QA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
    Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
    Front Immunol; 2018; 9():239. PubMed ID: 29515572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
    Darowski D; Kobold S; Jost C; Klein C
    MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy.
    Iriguchi S; Yasui Y; Kawai Y; Arima S; Kunitomo M; Sato T; Ueda T; Minagawa A; Mishima Y; Yanagawa N; Baba Y; Miyake Y; Nakayama K; Takiguchi M; Shinohara T; Nakatsura T; Yasukawa M; Kassai Y; Hayashi A; Kaneko S
    Nat Commun; 2021 Jan; 12(1):430. PubMed ID: 33462228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR T cells: Building on the CD19 paradigm.
    Globerson Levin A; Rivière I; Eshhar Z; Sadelain M
    Eur J Immunol; 2021 Sep; 51(9):2151-2163. PubMed ID: 34196410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Based CAR T Cells Produced by Lentiviral Transduction.
    Prommersberger S; Hudecek M; Nerreter T
    Curr Protoc Immunol; 2020 Mar; 128(1):e93. PubMed ID: 32150338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revolutionizing Cancer Treatments through Stem Cell-Derived CAR T Cells for Immunotherapy: Opening New Horizons for the Future of Oncology.
    Mishra HK; Kalyuzhny A
    Cells; 2024 Sep; 13(18):. PubMed ID: 39329700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.